Researchers reveal how a protein common in cancers jumps anti-tumor mechanisms

March 17, 2014

A Stony Brook University-led international team of infectious disease researchers have discovered how a cellular protein, called STAT3, which is overactive in a majority of human cancers, interferes with an antitumor mechanism in cells and therefore promotes the growth of cancer. The findings, to be published this week in the Proceedings of the National Academy of Sciences (PNAS) add to the understanding of cancer development and provide a basis for potentially new targeted methods to prevent and treat cancer.

In the paper, titled "STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation", lead author Sumita Bhaduri-McIntosh, MD, PhD, and colleagues made their discovery by using the Epstein-Barr virus (EBV) as a tool to probe fundamental development-related questions. EBV, which causes infectious mononucleosis, is carried by approximately 95 percent of the world's population, is implicated in several types of lymphoma and other cancers, and was the first virus identified to cause cancer in humans.

"Our findings add to the short list of known mechanisms by which a key cellular anti-tumor barrier is breached by STAT3 prior to cancer development," said Dr. Bhaduri-McIntosh, an Assistant Professor in the Departments of Pediatrics and Molecular Genetics and Microbiology at Stony Brook University School of Medicine and pediatric infectious diseases specialist at Stony Brook Children's Hospital. "Because STAT3 interferes with this innate anti-tumor mechanism in cells, the opposite occurs when blood cells are infected in the lab with the cancer-causing virus EBV, and the cells continue to divide – a necessary step in ."

More specifically, Dr. Bhaduri-McIntosh explained that STAT3 damages a cancer-suppressing cellular activity called the DNA damage response (DDR). Normally this response pauses cell division allowing for repair of damaged DNA. This new study shows that EBV not only causes DNA damage when it infects and replicates in cells, but it also very quickly turns up a , STAT3, which starts a chain reaction leading to a loss of this pause in cell division thereby promoting cell proliferation. This in combination with other pro-proliferative effects of the virus can lead to cancer.

Previous research has identified both STAT3 and another protein Chk1 as potential targets for cancer therapeutics. The authors write that their research results add fresh insight to anticancer drug development because they "provide a mechanistic link between the two, further lending support to these approaches."

Dr. Bhaduri-McIntosh emphasized that because STAT3 is involved in most cancers, their findings could potentially impact the prevention or treatment of several types of cancer – something that her lab is investigating. In addition to uncovering more about EBV-mediated cancers, the research is simultaneously helping the team to better understand EBV infections.

Paper coauthors include researchers from Stony Brook University, the National Institutes of Health, and research institutes in Germany and Australia.

Explore further: Cancer: Unraveling a mechanism behind cellular proliferation

More information: STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation, www.pnas.org/cgi/doi/10.1073/pnas.1400683111

Related Stories

Cancer: Unraveling a mechanism behind cellular proliferation

August 14, 2013
A hallmark of cancer is uncontrolled and sustained cell division. One particular overactive protein is implicated in this malfunction. EPFL scientists have discovered a complex mechanism that regulates this protein's activity ...

Immune system discovery could lead to EBV vaccine to prevent mono, some cancers

October 11, 2013
Development of a vaccine against Epstein-Barr virus (EBV) has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.

No 'brakes': Study finds mechanism for increased activity of oncogene in certain cancers

January 6, 2014
The increased activation of a key oncogene in head and neck cancers could be the result of mutation and dysfunction of regulatory proteins that are supposed to keep the gene, which has the potential to cause cancer, in check, ...

How a ubiquitous herpesvirus sometimes leads to cancer

October 10, 2013
You might not know it, but most of us are infected with the herpesvirus known as Epstein-Barr virus (EBV). For most of us, the virus will lead at worst to a case of infectious mononucleosis, but sometimes, and especially ...

Researchers design small molecule to disrupt cancer-causing protein

March 26, 2013
Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have developed a small molecule that inhibits STAT3, a protein that causes cancer. This development could impact the treatment of several ...

Young killer cells protect against infectious mononucleosis

December 19, 2013
More than 90 percent of all adults are carriers of the oncogenic Epstein-Barr Virus (EBV). Primary infection with this herpes virus as a young child is generally not linked to any symptoms, and usually offers life-long protection ...

Recommended for you

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.